Drug intelligence / Profile preview

PMG1015

Development stage: Phase 1
Lead developer: Pulmongene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PMG1015 is a monoclonal antibody that targets amphiregulin (AREG), developed as an immunomodulator for the treatment of idiopathic pulmonary fibrosis (IPF). By binding to AREG, PMG1015 is designed to inhibit pathways involved in fibrosis, potentially preventing organ scarring and failure. The drug is currently being evaluated in a phase 1b randomized, double-blind, placebo-controlled clinical trial to assess its safety, tolerability, pharmacokinetics, and immunogenicity in patients with IPF[1][2][3][4][5].

Other names: PMG-1015PMG1015PMG 1015

Targets

AREG (Amphiregulin)

Beyond the preview

Go deeper on PMG1015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMG1015.

Explore the full profile